Our first goal is to discover small molecules that disrupt the CD47-SIRPα protein-protein interaction (PPI) and develop them into ligand-selective CD47 inhibitors for use as research tools and pretherapeutic lead compounds for numerous cancers. The gene discussed is CD47; the disease is cancer.